WHO vaccine-preventable diseases: monitoring system. 2013 global summary

Last updated 20-Octl-2013 (data as of 16-Oct-2013)
Next overall update June 2014
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 5'8801 Infant (under 12 months) mortality rate: 142
GDP / capita (US$): 10'9401 Child (under 5 years) mortality rate: 182

Population data in thousands3

  2012  2011  2010  2009  2008  2000  1990  1980 
Total population 29'988  29'615  29'263  28'934  28'626  26'000  21'772  17'329 
Births 600  602  603  605  606  626  651  621 
Surviving infants 590  591  592  593  594  605  611  564 
Pop. less than 5 years 2'925  2'927  2'932  2'937  2'948  3'006  2'971  2'724 
Pop. less than 15 years 8'746  8'758  8'777  8'790  8'812  8'862  8'333  7'263 
Female 15-49 years 7'980  7'878  7'775  7'684  7'593  6'758  5'372  4'031 

Number of reported case

(Click for retrospective incidence data for Peru)
Diphtheria 44  185 
Japanese encephalitis
Measles 737  19'246 
Mumps
Pertussis 1'173  56  64  254  59  68  1'134  12'134 
Polio* 182 
Rubella
Rubella (CRS)
Tetanus (neonatal) 10  93  294 
Tetanus (total) 17  38  47  19  42  57  124  525 
Yellow fever 13  18  15  17  30 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV);"
"it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Peru)
Vaccine year result method % card seen                                                
BCG 2011  94  DHS   80.6  95  91  95  97  100  93  83  57 
DTP1 2011  93  DHS   80.6  100  94  97  99  100  91 
DTP3 2011  83  DHS   80.6  95  91  93  92  99  98  72  16 
HepB_BD          81  76  74  71  79  41 
HepB3          95  91  93  92  99  44 
Hib3          95  91  93  92  99  38 
JapEnc         
MCV 2011  90  DHS   80.6  94  96  94  91  90  64  23 
MCV2          63  70  57  42  17  97 
PCV1          100  97  95  66 
PCV3          89  82  83 
Pol3 2011  86  DHS   80.6  94  91  92  92  98  93  73  16 
Rota1          98  90  89  59 
Rota_last          91  84  75  41 
Rubella1          94  96  94  91  90 
TT2plus 2004  53  DHS   68.3  43  42  49  84  69 
PAB         
VAD1          50 
YFV          58  51  61  66  82 
  ° indicates that more than 1 survey occurred that year

  Next update: July 2014

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Peru)
BCG 95  91  95  97  97  93  83  57 
DTP1 99  94  97  97  97  99  89  39 
DTP3 95  91  93  93  93  98  72  16 
HepB3 95  91  93  93  93 
Hib3 95  91  93  93  93  43 
MCV 94  96  94  91  92  97  64  23 
PAB 85  85  85  67  67  66  19 
PCV3 89  82  83 
Pol3 94  91  92  92  93  93  73  16 
Rota_last 91  84  75  41 
YFV 58  51  61  66  82 

Number of districts in the country 1'836  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
 
   
/
|
|
\
Greater or equal to 90% 36
From 80 to 89% 13
From 50 to 79% 34
Less than 50% 18
Proportion of districts
not reporting DTP3 coverage
0
 

Immunization Schedule (2012 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DT 4, 6 months; Yes pertussis contrindication
DTwP 18 months; 4 years; Yes
DTwPHibHepB 2, 4, 6 months; Yes
HIB 2, 4 months; Yes pertussis contrindication
HPV 1st contact; +2, +4 months;
HepB birth; Yes and adults (1st contact; +2, +6 months) when requested
IPV 2, 4, 6 months; Yes For children with HIV+ mothers
Influenza 7-24, +1 months; Yes and risk groups
MMR 12 months; 4 years; Yes
MR under 5 years old and susceptible population
OPV 2, 4, 6 months; Yes
Pneumo_conj 2. 4, 12 months; Yes
Rotavirus 2, 4 months; Yes
Td 1st contact; +2, +4months; Yes
VitaminA from 6 months; No priority districts
YF 15 months; Yes population at risk zones

Immunizaton indicators

Indicator Expected answer 2012  2011  2010  2009  2008  2007  2006 

Planning and management

Multi-year plan (MYP) for immunization Yes/No/NR No  Yes  Yes  Yes  Yes  Yes  Yes 
What years does the MYP cover? number   2011-2015  2006-2010 y 2011-2015  2007-2012  2008 - 2012    2004 al 2006 
Nº of districts with microplans that include activities to raise immunization coverage number   1'834  1'834  1'834  1'833  34  1'832 

National Immunization Advisory Mechanism

Does the country have a standing technical advisory group on immunization? Yes/No/NR Yes  Yes  Yes         

System performance

Total number of districts in country number 1'838  1'834  1'834  1'834  1'833  1'833  1'832 
Nº districts with DTP3 coverage >=80% number 886  862  951  992  1'391  1'112  1'198 
% of districts with DTP3 coverage >=80% From 0 to 100% 48  47  52  54  76  61  65 
Nº districts with measles (MCV1) coverage >=95% number 596  658  726  613  806     
% of districts with MCV1 coverage >=95% From 0 to 100% 32  36  40  33  44     

Safety

Monitoring of Adverse Events Following Immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 
Does your country have a vaccine adverse events review committee? Yes/No/NR/ND Yes  Yes  Yes         

Finance

Percentage of routine vaccines funded by Government From 0 to 100% 100  100  100  100  100  100  96 

Maternal and neonatal tetanus (NT) elimination

NT eliminated Yes/No Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Sources

Unless otherwise specified, data provided by Member States through WHO-UNICEF Joint Reporting Form and WHO Regional offices.
 1  "The 2013 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  World Health Statistics 2012, data for 2011
 3  "United Nations, Population Division. The World Population Prospects - the 2012 revision". New York, 2013.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.